Doxorubicin liposomes as an investigative model to study the skin permeation of nanocarriers

Boakye, Cedar H. A.; Patel, Ketan; Singh, Mandip

doi:10.1016/j.ijpharm.2015.04.059

Cited by 47 publications

(14 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have previously used a novel synthesized cationic amphiphilic lipid that has the capability to temporarily fluidize the lipid matrix to improve the transdermal delivery of dual siRNAs and small molecules for the management of skin inflammatory conditions [9,25]. This lipid has pyrrolidinium physicochemical characteristics and has demonstrated to be a potent permeation enhancer for the skin delivery of therapeutic agents [26,27].…”

Section: Introductionmentioning

confidence: 99%

Novel amphiphilic lipid augments the co-delivery of erlotinib and IL36 siRNA into the skin for psoriasis treatment

Boakye

Patel

Doddapaneni

et al. 2017

Journal of Controlled Release

Self Cite

View full text Add to dashboard Cite

In this study, we demonstrate for the first time the concurrent transdermal delivery of erlotinib and IL36α siRNA as a potential dual therapy for psoriasis. The objectives were to develop and evaluate lipid nanocarriers (CYnLIP) using a novel pyrrolidinium lipid to disrupt the skin barrier for enhanced transdermal delivery. CYnLIP (132.00±6.23nm) had encapsulation efficiency of 49.04±2.54% for erlotinib. DSC confirmed encapsulation of erlotinib within CYnLIP. Atomic Force Microscopy demonstrated notable topographical changes in the stratum corneum of skin permeated with CYnLIP that were absent in skin hydrated with water. Peak force distance curves also exhibited a more permeable membrane for CYnLIP-incubated skin than hydrated skin. Permeation studies showed enhanced (p<0.01) skin retention of erlotinib by CYnLIP (40.76-fold) than solution and more pronounced fluorescence at deeper layers of the skin for fluorescein-labeled siRNA-CYnLIP than solution. The enhanced co-transdermal delivery of erlotinib and IL36α siRNA by CYnLIP efficaciously treated psoriatic-like plaques in C57BL/6 mice (PASI score of 1) compared to imiquimod-only treatment (PASI score of 4). IHC and western blotting revealed reduction in epidermal hyperplasia (Ki67) and in the dermal infiltration of inflammatory cytokines (IL36α, pSTAT3, TNFα, NFκB, IL23 and IL17) for erlotinib/IL36α siRNA-CYnLIP (p<0.05) comparable to Tacrolimus but markedly less than imiquimod-only treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Novel amphiphilic lipid augments the co-delivery of erlotinib and IL36 siRNA into the skin for psoriasis treatment

Boakye

Patel

Doddapaneni

et al. 2017

Journal of Controlled Release

Self Cite

View full text Add to dashboard Cite

show abstract

“…All samples were diluted in purified water and measured in thee replicates and results were expressed as the mean value ± standard deviation (SD). EE% of ETD-loaded formulations was calculated by with ultrafiltration process, using vivaspin centrifuge filter membrane (4000 rpm for 30 mins) and substitute in the equation 24…”

Section: Methodsmentioning

confidence: 99%

“…Different polymer and lipid-based nanocarriers were evolved, including liposomes, solid lipid nanoparticles, nanostructured lipid carriers (NLCs), nanoemulsions, and polymeric nanoparticles, etc. have been used to encapsulate these impermeable and macromolecular drugs and to enhance their surpassing through the stratum corneum (St.C) barrier 23,24…”

Section: Introductionmentioning

confidence: 99%

<p>A comparative study: the prospective influence of nanovectors in leveraging the chemopreventive potential of COX-2 inhibitors against skin cancer</p>

Aasy

Ragab

Sallam

et al. 2019

IJN

View full text Add to dashboard Cite

IntroductionThis study was conducted to elucidate the chemopreventive potential, cytotoxic, and suppression of cellular metastatic activity of etodolac (ETD)-loaded nanocarriers.MethodsTo esteem the effect of charge and composition of the nanovectors on their performance, four types of vectors namely, negative lipid nanovesicles; phosalosomes (N-Phsoms), positive phosalosomes (P-Phsoms), nanostructured lipid carriers (NLCs) and polymeric alginate polymer (AlgNPs) were prepared and compared. ETD was used as a model cyclo-oxygenase-2 (COX-2) inhibitor to evaluate the potency of these nanovectors to increase ETD permeation and retention through human skin and cytotoxicity against squamous cell carcinoma cell line (SCC). Moreover, the chemopreventive activity of ETD nanovector on mice skin cancer model was evaluated.ResultsAmong the utilized nanovectors, ETD-loaded N-Phsoms depicted spherical vesicles with the smallest particle size (202.96±2.37 nm) and a high zeta potential of −24.8±4.16 mV. N-Phsoms exhibited 1.5, and 3.6 folds increase in the ETD amount deposited in stratum corneum, epidermis and dermis. Moreover, cytotoxicity studies revealed a significant cytotoxic potential of such nanovector with IC50=181.76 compared to free ETD (IC50=982.75), correlated to enhanced cellular internalization. Its efficacy extended to a reduction in the relative tumor weight with 1.70 and 1.51-fold compared to positive control and free ETD, that manifested by a 1.72-fold reduction in both COX-2 and proliferating cell nuclear antigen mRNA (PCNA-mRNA) levels and 2.63-fold elevation in caspase-3 level in skin tumors relative to the positive control group with no hepato-and nephrotoxicity.ConclusionEncapsulation of ETD in nanovector enhances its in-vitro and in-vivo anti-tumor activity and opens the door for encapsulation of more relevant drugs.

show abstract

“…bupivacaine (31)), liposomes (e.g. doxorubicin (32)) and solid-lipid nanoparticles (e.g. minoxidil (33)).…”

Section: Materials Used For Drug Deliverymentioning

confidence: 99%

Porous Inorganic Drug Delivery Systems—a Review

et al. 2017

View full text Add to dashboard Cite

Innovative methods and materials have been developed to overcome limitations associated with current drug delivery systems. Significant developments have led to the use of a variety of materials (as excipients) such as inorganic and metallic structures; marking a transition from conventional polymers. Inorganic materials, especially those possessing significant porosity, are emerging as good candidates for the delivery of a range of drugs (anti-biotics, anti-cancer and anti-inflammatories), providing several advantages in formulation and engineering (encapsulation of drug in amorphous form, controlled delivery and improved targeting). This review focuses on key selected developments in porous drug delivery systems. The review provides a short broad overview of porous polymeric materials for drug delivery before focusing on porous inorganic materials (e.g. Santa Barbara Amorphous (SBA) and Mobil Composition of Matter (MCM)) and their utilisation in drug dosage form development. Methods for their preparation and drug loading thereafter are detailed. Several examples of porous inorganic materials, drugs used and outcomes are discussed providing the reader with an understanding of advances in the field and realistic opportunities.

show abstract

Doxorubicin liposomes as an investigative model to study the skin permeation of nanocarriers

Cited by 47 publications

References 41 publications

Novel amphiphilic lipid augments the co-delivery of erlotinib and IL36 siRNA into the skin for psoriasis treatment

Novel amphiphilic lipid augments the co-delivery of erlotinib and IL36 siRNA into the skin for psoriasis treatment

<p>A comparative study: the prospective influence of nanovectors in leveraging the chemopreventive potential of COX-2 inhibitors against skin cancer</p>

Porous Inorganic Drug Delivery Systems—a Review

Contact Info

Product

Resources

About